Literature DB >> 21395350

Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.

Rahul Jain1, Michael Grabner, Eberechukwu Onukwugha.   

Abstract

Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have been noted by various researchers. In this work, we consolidate across all sources of uncertainty, discuss the imbalanced attention to SA across different sources, and discuss criteria for conducting and reporting SA to help bridge the gap between guidelines and practice. Guidelines on how to perform SA have been published for many years in response to requests for greater standardization among researchers. Decision makers tasked with reviewing new health technologies also seem to appreciate the additional information conveyed by a robust SA, including the attention to important patient subgroups. Yet, past reviews have shown that there is a substantial gap between the guidelines' suggestions and the quality of SA in the field. Past reviews have also focused on one or two but not all three sources of uncertainty. The objective of our work is to comprehensively review all different sources of uncertainty and provide a concise set of criteria for conducting and presenting SA, stratified by common modelling approaches, including decision analysis and regression models. We first provide an overview of the three sources of uncertainty in a CEA (parameter, structural and methodological), including patient heterogeneity. We then present results from a literature review of the conduct and reporting of SA based on 406 CEA articles published between 2000 and mid-2009. We find that a minority of papers addressed at least two of the three sources of uncertainty, with no change over time. On the other hand, the use of some sophisticated techniques, such as probabilistic SA, has surged over the past 10 years. Lastly, we identify criteria for reporting uncertainty-robust SA and also discuss how to conduct SA and how to improve the reporting of SA for decision makers. We recommend that researchers take a more comprehensive view of uncertainty when planning SA for an economic evaluation.

Entities:  

Mesh:

Year:  2011        PMID: 21395350     DOI: 10.2165/11584630-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  40 in total

1.  The quality of reporting in published cost-utility analyses, 1976-1997.

Authors:  P J Neumann; P W Stone; R H Chapman; E A Sandberg; C M Bell
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

2.  Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter pylori.

Authors:  D J Pasta; J L Taylor; J M Henning
Journal:  Med Decis Making       Date:  1999 Jul-Sep       Impact factor: 2.583

Review 3.  Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.

Authors:  D L Lang; R Lopert; S R Hill
Journal:  J Clin Pharm Ther       Date:  2003-10       Impact factor: 2.512

4.  Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature.

Authors:  K E Agro; C A Bradley; N Mittmann; M Iskedjian; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

5.  Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.

Authors:  M Brisson; W J Edmunds
Journal:  Med Decis Making       Date:  2006 Sep-Oct       Impact factor: 2.583

Review 6.  Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Authors:  Laura Bojke; Karl Claxton; Mark Sculpher; Stephen Palmer
Journal:  Value Health       Date:  2009 Jul-Aug       Impact factor: 5.725

Review 7.  Time preference for health in cost-effectiveness analysis.

Authors:  J Lipscomb
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

8.  Cost-effectiveness of assertive community treatment for homeless persons with severe mental illness.

Authors:  A F Lehman; L Dixon; J S Hoch; B Deforge; E Kernan; R Frank
Journal:  Br J Psychiatry       Date:  1999-04       Impact factor: 9.319

9.  The measurement of patients' values in medicine.

Authors:  H Llewellyn-Thomas; H J Sutherland; R Tibshirani; A Ciampi; J E Till; N F Boyd
Journal:  Med Decis Making       Date:  1982       Impact factor: 2.583

Review 10.  Statistical approaches to handling uncertainty in health economic evaluation.

Authors:  Andrew H Briggs
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-06       Impact factor: 2.566

View more
  15 in total

Review 1.  Economic Evaluations of Mental Health Programs for Children and Adolescents in the United States: A Systematic Review.

Authors:  Jenna Y Sung; Corinne N Kacmarek; Jessica L Schleider
Journal:  Clin Child Fam Psychol Rev       Date:  2021-01-11

2.  Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

Authors:  Heejung Bang; Hongwei Zhao
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

Review 3.  The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.

Authors:  Elina Eleftheria Pliakos; Nikolaos Andreatos; Fadi Shehadeh; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2018-05-30       Impact factor: 26.132

4.  Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients.

Authors:  Irma M Puspitasari; Dewi Legianawati; Rano K Sinuraya; Auliya A Suwantika
Journal:  Int J Womens Health       Date:  2021-02-19

5.  Surgical management for displaced pediatric proximal humeral fractures: a cost analysis.

Authors:  Benjamin J Shore; Daniel J Hedequist; Patricia E Miller; Peter M Waters; Donald S Bae
Journal:  J Child Orthop       Date:  2015-02-20       Impact factor: 1.548

Review 6.  Cost-utility analysis in chronic kidney disease patients undergoing kidney transplant; what pays? A systematic review.

Authors:  Sameera Senanayake; Nicholas Graves; Helen Healy; Keshwar Baboolal; Sanjeewa Kularatna
Journal:  Cost Eff Resour Alloc       Date:  2020-05-19

Review 7.  A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer.

Authors:  Ava A John-Baptiste; Wei Wu; Paula Rochon; Geoffrey M Anderson; Chaim M Bell
Journal:  PLoS One       Date:  2013-05-06       Impact factor: 3.240

8.  A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.

Authors:  Ehsan Jozaghi; Andrew A Reid; Martin A Andresen; Alexandre Juneau
Journal:  Subst Abuse Treat Prev Policy       Date:  2014-08-04

9.  Evaluating services for perinatal asphyxia and low birth weight at two hospitals in Ghana: a micro-costing analysis.

Authors:  Christabel C Enweronu-Laryea; Eric Nsiah-Boateng; Hilary D Andoh; Audrey Frimpong-Barfi; Francis M Asenso-Boadi; Moses Aikins
Journal:  Ghana Med J       Date:  2019-12

10.  Cost-effectiveness analysis of a chronic back pain multidisciplinary biopsychosocial rehabilitation (MBR) compared to standard care for privately insured in Germany.

Authors:  M Hochheim; P Ramm; M Wunderlich; V Amelung
Journal:  BMC Health Serv Res       Date:  2021-12-24       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.